Regulus Therapeutics major shareholder Unloads $15,795 in Stock (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) major shareholder Alnylam Pharmaceuticals, Inc. sold 2,250 shares of Regulus Therapeutics stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $7.02, for a total transaction of $15,795.00. Following the sale, the insider now directly owns 6,093,400 shares in the company, valued at approximately $42,775,668. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down 0.85% during mid-day trading on Friday, hitting $7.02. 31,571 shares of the company’s stock traded hands. Regulus Therapeutics has a 52-week low of $5.40 and a 52-week high of $11.88. The stock has a 50-day moving average of $6.94 and a 200-day moving average of $7.94. The company’s market cap is $304.6 million.
Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Wednesday, August 6th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.19) by $0.10. Analysts expect that Regulus Therapeutics will post $-1.01 EPS for the current fiscal year.
Separately, analysts at FBR Capital Markets raised their price target on shares of Regulus Therapeutics from $14.00 to $15.00 in a research note on Thursday, August 7th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.50.
Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.